RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Human Metabolome Technologies P/E 2024

Human Metabolome Technologies P/E

18.66

Human Metabolome Technologies Dividend yield

1.56 %

Ticker

6090.T

ISIN

JP3794530000

As of May 31, 2024, Human Metabolome Technologies's P/E ratio was 18.66, a 27.03% change from the 14.69 P/E ratio recorded in the previous year.

The Human Metabolome Technologies P/E history

Human Metabolome Technologies Aktienanalyse

What does Human Metabolome Technologies do?

Human Metabolome Technologies Inc (HMT) is a Japanese company specializing in the research and development of metabolome analysis. HMT was founded in 2000 with the vision of gaining a deeper understanding of the metabolic processes of the human body in order to contribute to better healthcare. HMT's business model involves conducting metabolome analysis using mass spectrometry and other technologies to characterize the body's metabolic processes. This includes analyzing both healthy and diseased metabolism from samples such as blood, urine, or tissue in large numbers to identify biomarkers or signatures that can be used in the early detection, diagnosis, prognosis, and treatment of diseases. In this sense, HMT serves as an important partner for researchers in the pharmaceutical and biomedical industry who want to develop new diagnostic and therapeutic approaches. In recent years, HMT has developed a wide range of metabolome analysis technologies tailored to various applications. One of HMT's most important products is the Targeted Metabolomics Platform, which allows for the quantification of a variety of metabolites in samples such as blood or urine. This is an important step towards developing biomarkers that can serve as indicators of an organism's metabolic state. Another important platform of HMT is the Biomarker Discovery Platform, which specializes in the identification of biomarkers associated with specific diseases. This platform is often used by pharmaceutical companies to develop new drugs tailored to the specific needs of patients with certain diseases. HMT has also developed a comprehensive metabolome database that allows researchers and analysts to compare their own data with a variety of reference data. This database contains information on thousands of metabolites and allows researchers to better understand metabolic pathways and biomolecular interactions. In recent years, HMT has also increased its investment in clinical research to explore the potentials of metabolome analysis in the diagnosis and treatment of cancer, diabetes, cardiovascular diseases, metabolic disorders, and other diseases. In collaboration with clinics and universities, HMT has conducted several clinical studies to evaluate the effectiveness of metabolome analysis in the early detection and monitoring of diseases. HMT is headquartered in Tsuruoka, Japan, and is also active in the US, Europe, and Asia. The company employs over 100 people and has become a leading provider of metabolome analysis and services. In summary, HMT has developed unique expertise in the field of metabolome analysis and is able to offer a wide range of products and services to support researchers and analysts in the study of the metabolic processes of the human body. With a strong emphasis on innovation and clinical research, HMT will continue to play an important role in the development of new diagnostic and therapeutic approaches tailored to the specific needs of patients. Human Metabolome Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Human Metabolome Technologies's P/E Ratio

The Price to Earnings (P/E) Ratio of Human Metabolome Technologies is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Human Metabolome Technologies's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Human Metabolome Technologies is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Human Metabolome Technologies’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Human Metabolome Technologies Stock

What is the price-to-earnings ratio of Human Metabolome Technologies?

The price-earnings ratio of Human Metabolome Technologies is currently 18.66.

How has the price-earnings ratio of Human Metabolome Technologies changed compared to last year?

The price-to-earnings ratio of Human Metabolome Technologies has increased by 27.03% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Human Metabolome Technologies high compared to other companies?

Yes, the price-to-earnings ratio of Human Metabolome Technologies is high compared to other companies.

How does an increase in the price-earnings ratio of Human Metabolome Technologies affect the company?

An increase in the price-earnings ratio of Human Metabolome Technologies would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Human Metabolome Technologies affect the company?

A decrease in the price-earnings ratio of Human Metabolome Technologies would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Human Metabolome Technologies?

Some factors that influence the price-earnings ratio of Human Metabolome Technologies are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Human Metabolome Technologies pay?

Over the past 12 months, Human Metabolome Technologies paid a dividend of 10 JPY . This corresponds to a dividend yield of about 1.56 %. For the coming 12 months, Human Metabolome Technologies is expected to pay a dividend of 10 JPY.

What is the dividend yield of Human Metabolome Technologies?

The current dividend yield of Human Metabolome Technologies is 1.56 %.

When does Human Metabolome Technologies pay dividends?

Human Metabolome Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Human Metabolome Technologies?

Human Metabolome Technologies paid dividends every year for the past 0 years.

What is the dividend of Human Metabolome Technologies?

For the upcoming 12 months, dividends amounting to 10 JPY are expected. This corresponds to a dividend yield of 1.56 %.

In which sector is Human Metabolome Technologies located?

Human Metabolome Technologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Human Metabolome Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Human Metabolome Technologies from 9/1/2024 amounting to 15 JPY, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Human Metabolome Technologies pay the last dividend?

The last dividend was paid out on 9/1/2024.

What was the dividend of Human Metabolome Technologies in the year 2023?

In the year 2023, Human Metabolome Technologies distributed 0 JPY as dividends.

In which currency does Human Metabolome Technologies pay out the dividend?

The dividends of Human Metabolome Technologies are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Human Metabolome Technologies

Our stock analysis for Human Metabolome Technologies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Human Metabolome Technologies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.